Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioArctic ABBRCTF 80 EV-to-EBITDA is 59.24 as of Aug. 17, 2026, which is 277% above its 10-year median of 15.72. GuruFocus rates BRCTF with a GF Score™ of 80/100 and a GF Value™ of $49.56 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 401 Biotechnology companies, BioArctic AB ranks worse than 84.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioArctic AB's enterprise value is $2,756.8 Mil.
BioArctic AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $46.5 Mil. Therefore, BioArctic AB's EV-to-EBITDA for today is 59.24.
The historical rank and industry rank for BioArctic AB's EV-to-EBITDA or its related term are showing as below:
BRCTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.4 Med: 15.72 Max: 7292.95
Current: 60.2
During the past 11 years, the highest EV-to-EBITDA of BioArctic AB was 7292.95. The lowest was -397.40. And the median was 15.72.
BRCTF's EV-to-EBITDA is ranked worse than 84.79% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs BRCTF: 60.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BioArctic AB (OTCPK:BRCTF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioArctic AB's PE Ratio (TTM) for today is calculated as:
BioArctic AB's share price for today is $31.78.
BioArctic AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.255.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BioArctic AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRCTF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, BioArctic AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioArctic AB's EV-to-EBITDA falls into.
BioArctic AB's current Enterprise Value is $2,756.8 Mil.
BioArctic AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (BRCTF) has a EV-to-EBITDA of 59.24 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioArctic AB. This is 277% above median its historical median of 15.72. According to the industry distribution chart, BioArctic AB ranks #340 out of 401 companies in the Biotechnology industry, placing it in the top 84.8%.
Is BioArctic AB's EV-to-EBITDA too high?
BioArctic AB's current EV-to-EBITDA of 59.24 is 277% above median its 10-year median of 15.72. The Biotechnology industry median EV-to-EBITDA is 13.80. BioArctic AB's value of 59.24 is 329.3% above this industry median. Based on the distribution chart, BioArctic AB ranks #340 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioArctic AB has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #340 out of 401 companies for EV-to-EBITDA. This places BioArctic AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. BioArctic AB's value of 59.24 is 329.3% above this benchmark. While the company's 10-year median is 15.72 vs. the industry median of 13.80, BioArctic AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current EV-to-EBITDA of 59.24 is 329.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioArctic AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current EV-to-EBITDA is 59.24, which is 277% above median its own 10-year median of 15.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.56, compared to a current price of $31.78 — trading 35.9% below its estimated fair value. The current EV-to-EBITDA is 59.24, which is 277% above median its 10-year median of 15.72 and 329.3% above the Biotechnology industry median of 13.80. BioArctic AB's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current EV-to-EBITDA is 59.24 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $31.78 is trading 35.9% below its estimated GF Value™ of $49.56.
GuruFocus considers BioArctic AB to be Significantly Undervalued.
Key valuation signals for BRCTF:
EV-to-EBITDA: 59.24 (277% above median its 10-year median of 15.72)
GF Value™: $49.56 vs. price of $31.78 (35.9% below fair value)
Industry Position: 329.3% above the Biotechnology median (#340 of 401)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
80GF Score
Get the complete analysis for BRCTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
